Risk of toxicity versus risk of death: A complex equation in the management of highly curable malignancies Maurie Markman Editor’s Commentary 16 October 2008 Pages: 359 - 360
Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia Nicole LamannaMark A. Weiss Clinical Trials Report 16 October 2008 Pages: 363 - 364
Modern approaches to treating chronic myelogenous leukemia Javier Pinilla-IbarzCeleste Bello OriginalPaper 16 October 2008 Pages: 365 - 371
Myelodysplastic syndrome: An update on diagnosis and therapy Ahrin KoppelGary Schiller OriginalPaper 16 October 2008 Pages: 372 - 378
Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia Ryuzo Ohno OriginalPaper 16 October 2008 Pages: 379 - 387
Do six or eight cycles work better with CHOP-14 and rituximab? Paul A. Hamlin Clinical Trials Report 16 October 2008 Pages: 391 - 392
Management of relapsed diffuse large B-cell lymphoma Vaishalee Padgaonkar KenkreSonali M. Smith OriginalPaper 16 October 2008 Pages: 393 - 403
Novel therapies in peripheral T-cell lymphomas Hilary M. O’LearyKerry J. Savage OriginalPaper 16 October 2008 Pages: 404 - 411
Treatment of diffuse large B-cell lymphoma in the elderly: Strategies integrating oncogeriatric themes Pieternella J. LugtenburgPieter Sonneveld OriginalPaper 16 October 2008 Pages: 412 - 419
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma Manzurul A. SikderJonathan W. Friedberg OriginalPaper 16 October 2008 Pages: 420 - 426
The biology and management of uveal melanoma Takami SatoFei HanAkira Yamamoto OriginalPaper 16 October 2008 Pages: 431 - 438
Melanoma and the tumor microenvironment Jessie VillanuevaMeenhard Herlyn OriginalPaper 16 October 2008 Pages: 439 - 446
